Biohacking Boom: RFK Jr Pushes FDA Peptide Deregulation as NAD Market Soars to 12B

In the past 48 hours, the biohacking industry displays cautious optimism fueled by regulatory advocacy and surging consumer interest in peptides and nootropics.[1] RFK Jr. has intensified calls for FDA deregulation, pushing to reclassify 14 restricted peptides banned under a 2023 Biden-era rule that limited compounding pharmacies. He argues this would reduce black market risks and boost product quality, a stance echoed in recent podcasts contrasting last week's quieter coverage with no new FDA moves.[1][2]

No major deals, partnerships, or product launches emerged, though scrutiny persists on 2026 nootropic The Brain Song amid mixed reviews on efficacy and safety since its February debut.[1] The FDA's recent reversal on NMN—now lawful as a dietary supplement after industry petitions—marks a key win, enabling broader marketing.[2] Verified stats show the global NAD-support market, central to biohacking longevity, hit 3.45 billion dollars in 2024 and is forecast to reach 12.18 billion by 2033, driven by demand for cellular energy and anti-aging.[2]

Consumer behavior shifts toward self-optimization, with more bypassing regulations for gray-market peptides, differing from prior months' wearable focus.[1] No price changes or supply disruptions appear, but leaders like Kennedy champion medical libertarianism, favoring choice over 2025's strict enforcement.[1]

Compared to recent reporting, this period hums with advocacy momentum absent blockbuster disruptions, priming volatility if peptide rules ease.[1] Overall, biohacking edges mainstream via policy tailwinds and longevity hype.

For great deals today, check out https://amzn.to/44ci4hQ

This content was created in partnership and with the help of Artificial Intelligence AI